Rationale Initial drug abstinence (modeled here as Extinction Day 1, ED1) is a critical time point in the progression of addiction that is strongly influenced by stress and sex. ED1 induces corticosterone release in both sexes, and cocaine-seeking during ED1 can be mitigated by corticotrophin-releasing factor (CRF) antagonists more effectively in female rats. Oxytocin (OXT) is a neuropeptide that has several biological functions, including regulation of stress pathways. Methods To investigate a relationship between OXT, sex, and cocaine-seeking, we examined Fos on ED1 in OXT neurons of paraventricular (PVN) and supraoptic nuclei (SON) compared to homecage (cocaine experienced) or naïve male and female rats. We also administered OXT 30 min prior to ED1 testing or cued reinstatement testing. Results OXT neurons had decreased activity (as reflected by Fos protein) in PVN and SON on withdrawal day 1 (homecage) compared to naïve rats. Fos in OXT neurons was further decreased on ED1, compared to homecage controls, in both males and females even though in SON, cocaine exposure increased the number of OXT-expressing neurons. In addition, systemically administered OXT reduced cocaine-seeking during ED1 and cue-induced reinstatement of cocaine-seeking but delayed extinction, similarly among male and female rats. Conclusions These data indicate that OXT neurons in PVN and SON may be involved in cocaine-seeking during ED1 and support OXT as a possible therapeutic to decrease cocaine-seeking during initial abstinence and in response to cocaine-associated cues.
Introduction
Oxytocin (OXT) is a hypothalamic neuropeptide that is critically involved in a wide array of biological functions in both males and females, including maternal behavior, pair-bond formation, sexual arousal, social interaction and memory, and anxiety reduction (Keverne and Curley 2004; Lim and Young 2006; Neumann 2007) . Importantly, OXT administration exerts anxiolytic and anti-stress properties in animals (Ring et al. 2006 ) and exerts anxiolytic and prosocial effects in humans (Keverne and Curley 2004; Lim and Young 2006; Marazziti and Catena Dell'osso 2008) . Central OXT attenuates stress-induced neuroendocrine and molecular responses via the hypothalamic-pituitary-adrenal (HPA) axis and OXTsensitive brain regions such as the hypothalamus, dorsal hippocampus, and septum (Windle et al. 2004) . In a general sense, OXT can be conceived of as neuropeptide that modulates stress reactivity, as both direct effects on OXT receptors and secondary effects of modulating HPA axis function underlie the actions of OXT on stress (Van de Kar and Blair 1999; Landgraf and Neumann 2004) . OXT also modulates shifts in behavioral strategies in response to environmental stimuli (Amadei et al. 2017 ) by engaging corticostriatal circuitry implicated in reward seeking (Ragozzino et al. 2003; Block et al. 2007) . As stress and reward-seeking strategies are both substantially engaged in addiction phenotypes, OXT represents a significant neuromodulatory target for developing addiction therapeutics.
Although OXT is well characterized as a neurohormone that is released into the neurohypophysis from the paraventricular (PVN) and supraoptic nuclei (SON), there are also central OXT projections from the hypothalamus to brain nuclei implicated in addiction, including the ventral tegmental area, amygdala, nucleus accumbens, and prefrontal cortex. In behavioral studies, OXT has rewarding effects and produces a conditioned place preference (Liberzon et al. 1997) . Also, OXT administration reduces cocaine-induced hyperactivity (Kovacs et al. 1990) and stereotypies (Sarnyai et al. 1991) . In addition, OXT has been identified as a potential therapeutic for treatment of drug addiction. Indeed, administration of OXT decreases demand for cocaine in male rats, and demand for methamphetamine in males and females (Carson et al. 2010; Bentzley et al. 2014; Baracz et al. 2016; Cox et al. 2017) . As well, OXT directly infused into the nucleus accumbens, amygdala, or the hippocampus attenuated morphine tolerance and dependence (Sarnyai and Kovacs 1994) . Thus, there is strong evidence that OXT plays a role in the rewarding effects of abused drugs.
We previously reported that Extinction Day 1 (ED1) from repeated daily cocaine self-administration is a stressful event, marked by cocaine-seeking behavior, increased Fos expression in stress-responsive brain regions, and increased serum corticosterone levels. Cocaine-seeking on ED1, Fos expression in dorsal raphe, hippocampus, locus coeruleus, and periaqueductal gray, and circulating corticosterone both during and following the completion of the session, are greater in females than in males (Cason et al. 2016; Kohtz and AstonJones 2017) . In addition, cocaine-seeking on ED1 can be reduced by antagonizing corticotrophin-releasing factor-1 receptors to a greater extent among female rats (Cason et al. 2016) . We hypothesize that these substantial sex differences in ED1 behavior are driven by sex differences in underlying stress and anti-stress circuitries. Hence, we propose that downregulation of the anti-stress neurohormone OXT, on ED1, may increase cocaine-seeking during initial abstinence, cocaine-seeking persistence, and reinstatement. In this study, we utilized the ED1 model of initial abstinence from cocaine to examine activity of PVN and SON (as seen by expression of Fos protein) on ED1 compared to homecage controls. We then tested the therapeutic potential of pre-treatment with systemic OXT on cocaine-seeking on ED1 and cocaine-seeking persistence tested 2 weeks later, extinction resistance, and cued reinstatement in male and female rats.
Methods

Subjects
Male (325-450 g, n = 52) and female (225-300 g, n = 54) Sprague-Dawley rats (Charles River Laboratories;~55-60 days of age) were singly housed under a reversed 12 h:12 h light/ dark cycle (lights off 0600 h); all experiments were performed during the active cycle. Rats had free access to food and water and were housed in animal facilities at the Medical University of South Carolina (Fos and immunohistochemistry analyses) or Rutgers University (behavioral efficacy of OXT pre-treatment; both AAALAC-accredited). All experiments were approved by the Institutional Animal Care and Use Committees and conducted in accordance with the National Institutes of Health specifications outlined in their Guide for the Care and Use of Laboratory Animals: Eighth Edition (2011).
Jugular catheter surgeries
Animals were anesthetized with ketamine/xylazine (56.5/ 8.7 mg/kg) and given Carprofen (1.0 mg/kg) as an analgesic. Chronic in-dwelling catheters were constructed in-house and inserted as described previously (Smith et al. 2009 ). Animals were given Kefzol (10 mg, iv) and heparin (10 U, iv) starting 3 days following surgery and daily following selfadministration sessions. Rats were recovered from surgery for at least 1 week before self-administration training.
Drugs
Cocaine hydrochloride (NIDA, Research Triangle Park, NC) was dissolved in 0.9% sterile saline. OXT (Tocris) was dissolved in 0.9% saline and administered at 0.3 or 1.0 mg/kg, intraperitoneally (IP), 30 min prior to testing in all behavioral paradigms. At most, rats received three injections of OXT (ED1, Cued Reinstatement, Acclimated Motor Testing). There was a minimum of 3 weeks between OXT administration on ED1 and testing in cued reinstatement, and a minimum of 2 weeks between OXT injections prior to cued reinstatement and acclimated motor testing.
Cocaine self-administration
Self-administration sessions were conducted in standard operant conditioning chambers housed in sound attenuating cubicles and controlled via MED-PC IV software (MedAssociates, St Albans, VT) as described previously (Smith and Aston-Jones 2011) . Rats were trained in daily 2-h sessions to press an active lever for intravenous cocaine (0.2 mg/50 μl infusion for males, 0.16 mg/50 μl infusion for females). Different doses in infusions allowed females and males to achieve the same average number of lever presses, and cocaine-cue pairings, across the last 3 days of selfadministration by adjusting for weight differences and high cocaine intake in female rats, as per prior reports (Kohtz and Aston-Jones 2017) . Rats were trained for at least 10 days on a fixed ratio 1 (FR1) schedule of reinforcement to reach a criterion of > 10 cocaine infusions/day wherein light + tone cocaine-associated cues were presented with active lever presses. Each cocaine infusion was followed by a 20 s timeout period in which lever pressing produced neither cocaine nor cues. An inactive lever was also present; presses on it were tabulated but had no consequence.
Cocaine-seeking during ED1
Twenty-four hours after the final self-administration session, rats were tested in an initial extinction session (ED1). In this session, rats were exposed to the operant conditioning chamber for 90 min during which time presses on either lever had no consequence. Active lever pressing in the absence of cocaine reward or cues on ED1 was taken as a measure of cocaine-seeking during early abstinence, as previously reported (Feltenstein et al. 2011; Cason et al. 2016; Kohtz and Aston-Jones 2017) . Rats were injected with saline, 0.3 mg/ kg or 1.0 mg/kg OXT 30 min prior to testing.
Persistence, extinction, and cued reinstatement
Following the ED1 test, rats were returned to the homecage for 14 days of abstinence. Then, rats were returned to the context as in ED1 procedures, for a second extinction session (ED2) 14 days later on withdrawal day 15 (WD15). Active lever pressing during this session was taken as a measure of cocaine-seeking persistence following abstinence. Following this persistence test, rats were subjected to daily extinction sessions (90 min in the drug self-administration context in which lever presses had no consequence) for a minimum of 7 days, until they reached a criterion of < 25 lever presses on either lever. Once extinction criterion was met for three consecutive days, rats were tested with one dose of OXT (0.3 or 1.0 mg/kg) and a control injection of saline, in a counterbalanced manner 30 min before a test for cued reinstatement of cocaine-seeking, wherein light + tone cocaineassociated cues were presented with lever presses, but no cocaine was delivered. Rats were counterbalanced across test order in a Latin square design to control for carry-over effects of repeated OXT administration.
Locomotor behavior
One week following cued reinstatement testing, acclimated locomotor activity was measured in clear acrylic motor testing chambers (approximately 40 × 40 × 30 cm) equipped with Digiscan monitors (AccuScan Instruments, Inc., Columbus, OH) containing a 16 × 16 photobeam array. Photobeam breaks were recorded by DIGIPRO software (Version 1.4). Rats (n = 6/sex) were tested twice each; saline or OXT (1.0 mg/kg) was administered ip 30 min prior to testing in a counterbalanced fashion, with tests at least 2 days apart in the acclimated group (3 days of habituation in the locomotor testing chamber). A separate group of rats without prior cocaine experience was used to test the effects of OXT betweensubjects on novel locomotor behavior testing.
Sucrose progressive ratio
Male (n = 8) and female (n = 8) rats that were trained to lever press on an FR1 schedule for sucrose pellets in an operant conditioning chamber. Following a minimum of 7 days of FR1 for sucrose, rats were tested in a counterbalanced fashion for sucrose progressive ratio with the following ratio schedule within a session: 1, 2, 4, 6, 9, 12, 15, 20, 25, 32, 40, 50, 62, 77, 95, 118, 145, 178, 219, 268, 328, 402, 492, and 603 (Richardson and Roberts 1996) . Rats were administered 1.0 mg/kg OXT or saline vehicle ip 30 min prior to testing.
Tissue collection
Fifteen minutes following the ED1 session, some rats were deeply anesthetized and transcardially perfused using 0.9% saline followed by 4% paraformaldehyde. Homecage control rats were given ip injections of saline 22 h after the final selfadministration session and returned immediately to their homecage. Two hours later, those rats were sacrificed. Homecage controls and ED1 rats were paired for euthanasia date, such that each ED1-tested rat had a paired non-tested homecage control with similar FR1 experience. Homecage rats were perfused first, accounting for 15-min difference in euthanasia times between homecage-and ED1-tested rats. As Fos expression nominally is maximal at 90-120 min after neuronal stimulation, the ED1 rats were euthanized 135 min postinjection (105 min after the beginning of the ED1 test), and the homecage rats were euthanized 120 min post-injection (at the 24 h withdrawal timepoint). Euthanasia at 105 min after the beginning of ED1 captured the first 25 min of the ED1 session during which maximal responding occurs (Kohtz and AstonJones 2017 ). An additional group of rats without cocaine experience was handled daily for 10 days and euthanized directly from their homecages. Brains were collected, post-fixed for 24 h in 4% paraformaldehyde, transferred to a 20% sucrose solution, and stored at 4°C. Coronal sections (40 μm thick) were cut using a cryostat and processed for double-label immunohistochemistry for Fos and OXT, as described below.
Fos immunohistochemistry
Immunohistochemistry was carried out as previously described (e.g., Mahler and Aston-Jones 2012) . Sections were quenched in 0.3% H 2 O 2 phosphate-buffered saline (PBS) plus 0.1% azide and then blocked in 2% normal donkey serum (NDS) plus PBS-triton azide (PBST-Az) for 2 h. Sections were then incubated overnight (16 h) in PBST-Az-NDS with the addition of a rabbit primary antibody to Fos (1:10,000 Calbiochem, Santa Cruz, CA, Catalog no. PC38, Lot no. D00148958). Sections were then incubated for 2 h in biotinylated donkey anti-rabbit secondary antibody (1:500, Jackson ImmunoResearch Laboratories, West Grove, PA). Sections were visualized via 32,32-diaminobenzidine (DAB) with 0.0002% H 2 O 2 in 0.05 M Tris buffer plus nickel ammonium sulfate for~4.5 min to produce a dark purple reaction product (Mahler and Aston-Jones 2012) . Sections were then transferred to the second primary antibody for OXT visualization. OXT was incubated with a donkey primary antibody to OXT (1:5000 MAB5296, EMD Millipore, Burlington, MA) in PBST-NDS (16 h). Sections were then incubated for 2 h in biotinylated donkey anti-mouse secondary antibody (1:500, Jackson ImmunoResearch Laboratories, West Grove, PA). Sections were visualized via 32,32-diaminobenzidine (DAB) with 0.0002% H 2 O 2 in 0.05 M Tris buffer without nickel ammonium sulfate for~4.5 min to produce a brown reaction product (Mahler and Aston-Jones 2012) , and then mounted, dehydrated, and cover slipped for imaging. A minimum of three sections per rat per region were analyzed for OXT and Fos labeling in the same sections. Sections were separated into SON (Fig. 1a) , PVN-rostral (PVNr; Fig. 1b ), PVN-mid (PVNm; Fig. 1c ), or PVN-caudal (PVNc; Fig. 1d ).
Statistical analysis
Independent t tests, Pearson's-R correlations, or one-or twoway analysis of variance (ANOVA) were used to compare differences between groups for behavioral responding or for neuronal activation. Post hoc comparisons were conducted using Bonferroni's multiple comparisons test. All data passed the Shapiro-Wilk's test of normality with W values in the range of 0.7756-0.9998, p > 0.05.
Results
Fos in OXT neurons decreased on ED1 in a sexand region-specific manner
To identify the response of OXT neurons in PVN and SON to cocaine withdrawal and cocaine-seeking behavior, we examined Fos expression in OXT neurons in male and female rats without cocaine experience (no-cocaine baseline), 24 h withdrawal from cocaine (homecage), or following engagement in ED1 cocaine-seeking (ED1).
Paraventricular nucleus-rostral
Cocaine self-administration followed by 24 h withdrawal (homecage) decreased Fos expression in PVNr OTC+ neurons compared to no-cocaine (baseline) controls, and exposure to the context previously associated with cocaine (ED1) decreased Fos expression in OTC+ neurons compared to homecage or baseline controls (Fig. 2a) ; these results were similar for male and female rats. There was a significant main effect of test condition (no-cocaine baseline, 24 h withdrawal, or ED1) to decrease Fos expression in OTC+ neurons [F(2,36) = 42.63, p < 0.0001], but no main effect of sex nor an interaction between sex and ED1 exposure on the percentage of OTC+ neurons that were also Fos+ in PVNr.
The percentage of PVNr OXT+ neurons that were also Fos+ significantly correlated to ED1 cocaine-seeking in males [R 2 = 0.53, p < 0.05], but not in females or when collapsed across sex. However, it is notable that all of the values for numbers of Fos+/OXT+ neurons in the ED1 group were less than 10, limiting the ability to measure differences in Fos expression in OXT neurons among groups.
There were no significant effects of test condition (no-cocaine baseline, homecage 24 h withdrawal, or ED1) or sex (male, female) on the number of OXT+ neurons in rostral PVN (Table 1) .
Paraventricular nucleus-mid
Our results indicate an interaction between sex and test condition [F(2,37) = 5.818, p < 0.005] wherein cocaine experience (i.e., homecage or ED1) significantly reduced Fos in PVNm OXT+ neurons in males compared to no-cocaine baseline controls. In contrast, only ED1 exposure decreased Fos in OXT+ neurons in females (Fig. 2b) . Notably, the percentage of PVNm OXT+ neurons that were also Fos+ significantly correlated to ED1 cocaine-seeking among females (R 2 = 0.29, p < 0.05) and when collapsed across sex (R 2 = 0.21, p < 0.05) but did not significantly correlate among males, indicating that PVNm may correspond more to cocaine-seeking behaviors in females than males.
There were no significant effects of test condition (no-cocaine baseline, homecage 24 h withdrawal, or ED1) or sex (male, female) on the number of OXT+ neurons in PVNm (Table 1) .
Paraventricular nucleus-caudal
In males, ED1 exposure decreased Fos in PVNc OXT+ neurons [post hoc F(2,15) = 7.676, p < 0.01] compared to 24 h withdrawal or no cocaine baseline controls, reflecting a significant main effect of sex [F(1,31) = 5.040, p < 0.05] and of test condition [F(2,31) = 5.794, p < 0.01]. There were no effects of cocaine withdrawal or ED1 exposure on Fos in PVNc OXT+ neurons of female rats. These results indicate that PVNc OXT+ neurons may respond to engagement in cocaine-seeking behavior to a greater extent in males compared to females; however, the percentage of PVNc OXT+ neurons that were also Fos+ did not correlate to ED1 cocaine-seeking.
There were no significant effects of test condition (no-cocaine baseline, homecage 24 h withdrawal, or ED1) or sex (male, female) on the number of OXT expressing neurons in PVNc (Table 1) .
Supraoptic nucleus
Sex differences emerged among SON OXT+ neurons dependent on test condition. There was a significant interaction between sex and test condition on the percentage of SON OXT+ neurons that were also Fos+ [F(2,37) = 4.905, p < 0.01; Fig. 2d ]. In females, cocaine self-administration followed by 24 h withdrawal (homecage) decreased Fos expression in OXT+ neurons compared to no-cocaine (baseline) controls, and exposure to the context previously associated with cocaine (ED1) decreased Fos expression in OXT+ neurons further. In contrast, in males, only ED1 significantly reduced Fos in OXT+ neurons. The percentage of SON OXT+ neurons that were also Fos+ did not significantly correlate to ED1 cocaine-seeking among males, females, or when collapsed across sex. However, it is notable that the majority of values for numbers of Fos+/OXT+ neurons in the ED1 group were less than 10, limiting the ability to measure differences in Fos expression in OXT neurons among groups. There was a significant main effect of test condition (nococaine baseline, homecage 24 h withdrawal, or ED1), but not sex, on the number of OXT+ neurons in SON (Table 1) wherein cocaine exposure increased the number of OXT-expressing neurons in SON [F(1,37) = 8.822; p < 0.001]. The number of SON OXT+ neurons negatively correlated to the percentage of OXT+ neurons that were also Fos+ in females (R 2 = 0.48; p < 0.05), but not males. However, there were significantly less total Fos+/OXT+ neurons on ED1 (2.88 ± 0.91) compared to homecage (7.58 ± 2.07) or no cocaine controls [11.01 ± 1.66; F(2,22) = 7.422, p < 0.05], indicating that the percentage decrease in Fos+/OXT+ neurons on ED1 was not accounted for by an increase in total OXT-expressing neurons in SON.
Systemic administration of OXT was more effective in reducing cocaine-seeking behavior on ED1 in female than male rats Fig. 2 Fos expression in OXT neurons of PVN and SON nuclei is decreased in males and females on ED1 compared to no cocaine (baseline) and homecage controls. a Percentages of OXT+ neurons that are also Fos+ in rostral PVN for males (no cocaine/baseline n = 8, homecage n = 5, ED1 n = 6) and females (no cocaine/baseline n = 5, homecage n = 7, ED1 n = 11). ED1 exposure decreased the percentages of OXT neurons that are Fos+ in both males and females, compared to homecage controls; *significant differences from respective baseline, p < 0.05.^Significant differences from respective homecage, p < 0.05. b PVNm. Percentages of OXT+ neurons that are also Fos+ in PVNm for males (no cocaine/baseline n = 4, homecage n = 5, ED1 n = 11) and females (no cocaine/baseline n = 5, homecage n = 6, ED1 n = 12). ED1 exposure decreased the percentage of OXT neurons that are also Fos+ in females only, compared to female homecage controls; *significant differences from respective baseline, p < 0.05.^Significant differences from respective homecage, p < 0.05. c Caudal PVN. Percentages of OXT neurons that are Fos+ in PVNc for males (no cocaine/baseline n = 4, homecage n = 6, ED1 n = 6) and females (no cocaine/baseline n = 6, homecage n = 4, ED1 n = 11). ED1 exposure decreased the percentage of OXT neurons that are Fos+ in males only, compared to male homecage controls; *significant differences from male baseline, p < 0.05. Significant differences from male homecage, p < 0.05. d Supraoptic nucleus. Percentages of OXT neurons that are Fos+ in SON for males (no cocaine/baseline n = 7, homecage n = 4, ED1 n = 10) and females (no cocaine/baseline n = 5, homecage n = 6, ED1 n = 11). ED1 exposure decreased the percentage of OXT neurons in SON that are Fos+ in both males and females compared to homecage or to no-cocaine controls; *significant differences from respective baseline, p < 0.05.^Significant differences from respective homecage, p < 0.05 kg, ip) or saline vehicle 30 min prior to the ED1 session in the operant conditioning box. Rats then underwent a 90-min ED1 session during which Bactive^lever presses had no outcome but were recorded as a measure of cocaine-seeking behavior. Cocaine-seeking behavior on ED1 was greater in both males [t(1,16) = 2.694, p < 0.05] and females [t(1,16) = 6.179, p < 0.0001] when compared to active lever presses during the last 3 days of self-administration (Bextinction burst^), as per prior reports (Kohtz and Aston-Jones 2017). As well, females had higher active lever pressing on ED1 compared to males when administered saline vehicle [t(1,15) = 3.691, p < 0.005]. These effects were independent of estrous cycle phase, as one-way ANOVA analyses reveal no significant effect of estrous cycle phase on ED1 cocaine-seeking in female rats (Fig. 3b) . Systemic OXT administration had greater efficacy in females compared to males to dose-dependently reduce active lever responding OXT (Fig. 3a) , as shown by two-way ANOVA analyses wherein there was a significant interaction between sex and drug condition [F(2,39) = 5.384, p < 0.01]. There was a statistically significant effect of OXT dose-dependently decrease ED1 cocaine-seeking in both sexes [F(2,39) = 64.42, p < 0.0001].
Following ED1, rats were returned to their homecages and underwent a period of abstinence for 2 weeks. Rats were then returned to the operant conditioning chamber and were tested for ED2 responding (lever presses had no outcome but were recorded) to determine if the effects of OXT treatment on ED1 were persistent. Our data indicate no significant sex differences in cocaine-seeking behavior on ED1, and that OXT administration on ED1 dose-dependently increased the persistence of cocaine-seeking as measured on ED2 (Fig. 3c) . A two-way ANOVA comparing sex and drug condition revealed a significant main effect of ED1 OXT administration [F(2,39) = 3.873, p < 0.05], but no main effect of sex nor an interaction to influence responding on ED2.
Notably, when persistent cocaine-seeking (after 2 weeks abstinence as above) is compared to initial cocaine-seeking behavior on ED1, males show greater initial extinction resistance (Fig. 3a, c) . A repeated measures ANOVA between test day (ED1 vs ED2) and treatment condition on ED1 (OXT or saline) among males revealed a main effect of day [F(1,20) = 26.64, p < 0.0001], and a main effect of ED1 treatment [F(2,20) = 3.851, p < 0.05]. In addition, there was an interaction between test day and ED1 treatment [F(2,20) = 15.70, p < 0.0001], wherein male rats administered OXT (1.0 mg/ kg) on ED1 had dose-dependently greater cocaine-seeking behaviors on ED2. In females, there was a main effect of ED1 treatment, [F(1,18) = 6.945, p < 0.005] and a main effect of day [F(1,18) = 8.475, p < 0.01] wherein females administered saline on ED1 showed decreased cocaine-seeking behaviors on ED2 (e.g., showed extinction), albeit not to criterion. In addition, there was an interaction between test day and ED1 treatment in females [F(1,18) = 31.78, p < 0.0001], such that females that were administered OXT (1.0 mg/kg) on ED1 had dose-dependently greater cocaine-seeking behaviors on ED2 than those administered saline on ED1.
OXT administration reduced cued reinstatement of cocaine-seeking to a greater extent in female than male rats
After the ED2 session, rats experienced daily 2-h extinction sessions for a minimum of 7 days prior to testing for cued reinstatement of responding. Females were overall more extinction resistant (more days to extinction criterion) than males. Two-way ANOVA analyses on the number of days to reach extinction criteria revealed a main effect of sex [F(1,29) = 8.604, p < 0.05] wherein females took longer to reach extinction criteria compared to males. One milligram per kilogram, but not 0.3 mg/kg OXT administered on ED1, produced significant extinction resistance in males (Fig. 3d) and facilitated extinction in females (Fig. 3e) . There was an interaction between sex and OXT administration on ED1 to influence the number of days to reach extinction criteria Fig. 1d) 35.31 ± 6.6 45.05 ± 6.9 40.2 ± 4.6 28.9 ± 6.1 26.4 ± 3.7 39.6 ± 7.2 Supraoptic nucleus (AP − 1.52; Fig. 1a) 38.49 ± 4.7 31.10 ± 5.0 59.21 ± 10.5* 47.7 ± 5.3* 64.5 ± 4.1* 57.7 ± 5.8* a Systemic administration of OXT (0.3 or 1.0 mg/kg, ip) 30 min prior to ED1 testing decreased cocaine-seeking behavior as measured by active lever presses, in males (saline n = 9, 0.3 mg/kg n = 8, 1.0 mg/kg, n = 6) and females (saline n = 8, 0.3 mg/kg n = 7, 1.0 mg/kg, n = 7), compared to saline-administered controls; *p < 0.05. Among saline controls, females displayed greater cocaine-seeking behavior compared to males; $p < 0.05. b ED1 responding across the estrous cycle in saline-administered rats (diestrous n = 5, proestrous n = 5, estrous n = 10, metestrous n = 4). No significant differences were observed. c Following ED1 testing, rats were returned to their homecages for 14 days of forced abstinence. When returned to the self-administration context for ED2 testing on WD15 (relapse test, no cocaine or cues), males that had been administered saline or OXT (0.3 mg/kg) on ED1 did not show extinction of the cocaineseeking phenotype (e.g., ED2 responding was similar to ED1 saline responding), but those administered 1.0 mg/kg OXT showed increased responding on ED2 compared to ED1. In contrast, females administered saline or OXT (0.3 mg/kg) showed extinction of the cocaine-seeking phenotype on ED2 compared to ED1. However, females administered OXT (1.0 mg/kg) on ED1 had greater cocaine-seeking behavior on ED2 compared to those previously administered saline; *p < 0.05. d Survival curve depicting rate of extinction in male rats (n = 6/group) following systemic OXT administration on ED1 and 2 weeks of abstinence. Day 0 represents responding on the first test day after 2 weeks of abstinence. *Significant differences from ED1 saline-administered controls; *p < 0.05. e Survival curve depicting rate of extinction in female rats (n = 6/group) following systemic OXT administration on ED1 and 2 weeks of abstinence, illustrated as for d. f Systemic administration of OXT (0.3 or 1.0 mg/kg, ip) 30 min prior to cued reinstatement testing decreased cocaine-seeking behaviors as measured by active lever presses, in males (saline n = 19, 0.3 mg/kg n = 9, 1.0 mg/kg, n = 10) and females (saline n = 18, 0.3 mg/kg n = 8, 1.0 mg/kg, n = 11) compared to salineadministered controls; *p < 0.05 wherein females administered OXT on ED1 took fewer days, primarily when administered 0.3 mg/kg OXT, and males administered OXT on ED1 took more days, to meet extinction criteria irrespective of OXT dose [F(2,29) = 3.826, p < 0.05]. Rats were administered OXT (0.3 or 1.0 mg/kg) or saline vehicle 30 min prior to testing for cued reinstatement of cocaine-seeking. OXT effectively decreased cued-induced cocaine-seeking in both males and females. There was a significant interaction between sex and drug condition wherein OXT was effective at both 0.3 and 1.0 mg/kg to reduce cued reinstatement in females, but in males, only the 1.0 mg/kg dose was effective [F(2,69) = 3.343, p < 0.05] (Fig. 3f) .
OXT administration reduced non-motivated locomotor activity, but not operant responding for sucrose reward
In naïve animals, we investigated whether systemic OXT administration influenced simple, non-motivated locomotor activity in a novel, open-field locomotor testing chamber. We found that systemic OXT significantly decreased total distance traveled to a greater extent in females compared to males [F(1,20) = 4.52, p < 0.05] (Fig. 4a) . We also found that there was a significant main effect of OXT administration to reduce motor behavior in the novel locomotor testing chamber [F(1,20) = 26.67, p < 0.001] independent of sex.
Rats that were tested in cued reinstatement were returned to their homecages for 1 week. Then, these rats were acclimated to the locomotor testing chamber for 3 days prior to testing. There was a significant main effect of OXT (1.0 mg/kg) administration to reduce motor behavior in the acclimated environment [F(1,22) = 10.21, p < 0.05]; however, we observed no interaction between sex and drug condition, and no effect of sex on activity in the acclimated condition (Fig. 4b) .
A separate group of rats was used to test whether systemic OXT (1.0 mg/kg) influenced progressive ratio lever responding for sucrose reward (Fig. 4d) . We observed no effects of OXT on sucrose progressive ratio measures in either males or females. Two-way ANOVAs indicated no significant interactions between sex and OXT, no main effects of sex or OXT, on sucrose progressive ratio breakpoints or number of pellets acquired. These results show that although OXT can reduce simple, non-motivated locomotor activity, it does not affect motivated operant behavior for a natural food reward. This indicates that the effects obtained for OXT on cocaine ED1 and reinstatement behaviors were not due to general nonspecific effects on lever pressing abilities.
Discussion
Our results support previous findings demonstrating that there are sex differences in operant cocaine-seeking during initial abstinence, wherein females exhibit greater cocaine-seeking than males (Lynch et al. 2002; Fuchs et al. 2005; Kippin et al. 2005; Feltenstein et al. 2011; Holly et al. 2012; Cason et al. 2016) . Moreover, our results indicate that the increased cocaine-seeking during initial abstinence (ED1) is accompanied by decreased Fos activation of PVN and SON OXT neurons. Pre-treatment with systemic OXT decreased cocaineseeking on ED1, as well as when administered prior to cued reinstatement, in female and male rats. Prior reports indicate that administration of OXT decreased cocaine demand in male rats, and demand for methamphetamine in males and females (Bentzley et al. 2014; Cox et al. 2017; Westenbroek et al. 2017) , further supporting OXT's therapeutic potential. However, our results also indicate that an acute administration of OXT on ED1 can delay context extinction, particularly in male rats.
Systemic administration of OXT has poor blood-brain barrier penetrance (Ermisch et al. 1985; Lee et al. 2018) . However, previous studies recapitulated effects of systemic OXT administration with intracerebroventricular or sitespecific intracranial infusions across a number of behavioral tasks and species (Ring et al. 2006; Baracz et al. 2012) . As well, peripheral administration of OXT induces Fos expression and activity of OXT neurons in the paraventricular nucleus, perhaps via stimulation of their peripheral terminals (Carson et al. 2010; Leong et al. 2017) . We speculate that OXT administered peripherally may induce endogenous central OXT release as previously proposed by others (Rossoni et al. 2008; Neumann et al. 2013; Leong et al. 2017) .
Numerous studies reveal region-, sex-, and cycle-specific differences in expression of OXT and OXT receptors associated with stress and hormonal state. For example, OXT mRNA expression in female rats is higher during proestrous than diestrous; in fact, little or no OXT mRNA expression is observed during diestrous (Bale et al. 1995) . We found that ED1 cocaine-seeking is consistently independent of the hormonal cycle in females (Fig. 3b) . However, OXT activity appears to vary markedly with stress, e.g., forced swim test (Lu et al. 2015) or ED1 (Cason et al. 2016; Kohtz and Aston-Jones 2017) as reported herein. We hypothesize that the increased circulating stress steroid levels produced by engagement in ED1 cocaine-seeking in both males and females and subsequent effects on OXT signaling obfuscate sexual dimorphisms in OXT expression.
Sex differences in OXT function in the brain in response to challenge (e.g., stress, cocaine) may relate to sexually divergent roles of OXT in estradiol-dependent behaviors. OXT administration induces maternal and sexual behaviors in females (Pedersen and Prange 1979; Pedersen et al. 1982; Insel 1990; Champagne et al. 2001) , and the most dramatic effects of steroids on OXT in the PVN are seen post-partum during mother-infant bond formation (Insel 1990; Keverne and Curley 2004) . These data may indicate greater responsivity of the female OXT system compared to males that confers greater efficacy of exogenous OXT on behavior.
Endogenous as well as exogenously administered OXT influences stress response mechanisms. Previous studies show that brain OXT inhibits activation of the HPA axis (Windle et al. 2004; Neumann 2007) . OXT engages a positive feedback loop via somatodendritic release of OXT in PVN (Leng et al. 1999) , OXT autoreceptors, and intracellular calcium signaling independent of voltage-gated calcium channels that results in increased release of OXT at terminals (Lambert et al. 1994; Dayanithi et al. 2000; Ludwig et al. 2002) . Notably, OXT also interacts with corticotropin-releasing hormone (CRF) neurons, and intracranial infusions of an OXT receptor antagonist into PVN can enhance basal and stressinduced secretion of adrenocorticotropic hormone (ACTH) and corticosterone (Neumann et al. 2000) . Based on these data, we speculate that OXT may exert a tonic inhibitory tone on the HPA axis. We previously found that ED1 exposure induced corticosterone secretion in male and female rats (Kohtz and Aston-Jones 2017) ; this is consistent with the above hypothesis for CRF-OXT interactions. We also suggested that ED1 represents a stressful time point in the addiction cycle due to the absence of expected drug reward (Cason et al. 2016; Kohtz and Aston-Jones 2017) and that this might engage this CRF-OXT circuit. Indeed, we found that a selective CRF1 receptor antagonist significantly decreased ED1 cocaine-seeking (Cason et al. 2016) . Also, previous research from our lab found that OXT substantially reduced drugseeking in other stressful paradigms, such as primed, cued, or yohimbine-induced reinstatement of methamphetamine seeking (Cox et al. 2013) , or cocaine demand and cued cocaine-seeking (Bentzley et al. 2014) . Here, we extend those findings to show reduced cocaine-seeking in ED1 following systemic administration of OXT, and that OXT's therapeutic efficacy is greater in females compared to males. In addition, we show that activity of OXT neurons is significantly attenuated by cocaine withdrawal and engagement in cocaine-seeking, in a sex by PVN subregion-specific manner. Systemic OXT administration reduced locomotor behavior in novel and acclimated test chambers (females n = 6, males n = 7), but not lever responding during sucrose progressive ratio (n = 8/sex). a Systemic administration of OXT (1.0 mg/kg, ip) 30 min prior to testing decreased locomotor behavior in a novel chamber as measured by total distance traveled (cm), in males and females, compared to saline controls; *p < 0.05. b Administration of OXT (1.0 mg/kg, ip) 30 min prior to testing in a familiar chamber (after acclimation for 2 days), decreased locomotor behavior as measured by total distance traveled (cm), in males and females, compared to saline administered controls; *p < 0.05. c OXT administration (1.0 mg/kg, ip) did not alter progressive ratio breakpoints, or the number of active lever presses made during sucrose progressive ratio testing in males or females (d) Similar to prior reports, we observed an effect of systemic OXT to suppress non-motivated locomotor behavior, irrespective of prior OXT experience, but not active lever pressing for sucrose during progressive ratio responding (Cox et al. 2013; Zhou et al. 2015a, b) . Repeated OXT administration during adolescence (PND 28-37) inhibits progressive ratio for methamphetamine in adulthood (Hicks et al. 2016) ; however, repeated intermittent OXT administration (as reported herein) does not alter active lever presses or cocaine intake in female rats (Leong et al. 2016 ). In addition, prior reports also indicate that although FR1 sucrose is affected by OXT in naïve rats (Zhou et al. 2015a) , progressive ratio responding is not (Cox et al. 2013) . As the amount of active lever pressing during sucrose progressive ratio responding is similar to that of ED1 after cocaine, our results indicate that the effects of OXT on ED1 and reinstatement lever responding are not due to simple motor effects; instead, motor actions of OXT appear restricted to non-motivated behavior. One possibility is that OXT is effective in reducing reward seeking under stressful contexts (e.g., drug abstinence or extinction), but not when rewards are available to self-administer.
Region-specific sex differences in PVN OXT activity on ED1 may contribute to increased ED1 cocaine-seeking behavior in female rats. Here, we show that in males only, PVNr OXT neurons exhibit less Fos on ED1 and negatively correlate to cocaineseeking behavior, whereas, in females only, PVNm OXT neurons are less Fos-responsive on ED1 and negatively correlate to cocaine-seeking behavior. Notably, PVNm OXT neurons have stronger projections to pre-locus coeruleus (LC) and the nucleus of the solitary tract (NTS) compared to projections from PVNr/c, exerting an inhibitory tone on NE release from LC or NTS (Geerling et al. 2010; Uchoa et al. 2013) . Stress-responsive norepinephrine (NE) neurons in LC and NTS are more Fosactivated on ED1 in females compared to males and are implicated in driving the female phenotype of increased initial cocaine-seeking (Cason et al. 2016; Kohtz and Aston-Jones 2017) . Our results support and extend prior research indicating that stress-responsive neural circuitry may drive sex differences in cocaine-seeking behaviors (e.g., greater seeking in female rodents) while providing further evidence that Banti-stress^phar-macotherapies (i.e., OXT, CRF antagonists, NE antagonists) are more effective in reducing cocaine-seeking in females than in males. Investigating interactions between OXT and stress responsive signaling targets is a goal for future studies.
In summary, we found that OXT neurons are less active during initial abstinence from cocaine self-administration and further decreased their activity during ED1 exposure. This reduction in OXT neuron activity following cocaine exposure may contribute to drug seeking during initial abstinence. Indeed, systemic administration of OXT, which we speculate may replace endogenous reductions induced by cocaine experience and ED1 exposure, decreased cocaine-seeking behavior during initial abstinence. However, these effects were transient and, in fact, high-dosage OXT (1.0 mg/kg) delayed extinction. Thus, exogenously administered OXT may be a potential therapeutic target for mitigating cocaine craving during the initiation of abstinence and in the presence of cocaineassociated cues.
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